we will describe the current status of personalized medicine for chronic, complex diseases using chronic obstructive pulmonary disease (COPD) as an example. After looking at the genotypic and ...
It's the first ever biologic medicine for COPD in either country. Specifically, the drug is indicated in both countries as an add-on treatment for patients with inadequately controlled COPD and an ...
The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year, up 15%. COPD could open up a massive new market for the drug, which still has ...